Patients with bruxism received bilateral masseter muscle injections of 25 units of botulinum toxin type A (Botox®, Allergan) per side. T-Scan occlusal force measurements were performed at baseline (T0) and day 15 post-injection (T1). Participants were stratified into low-angle and normal-angle subgroups based on GoGn/SN cephalometric angle.

Botulinum toxin type A (Botox®, Allergan, Irvine, CA, USA) was injected bilaterally into the masseter muscle at a dose of 25 units per side (50 units total per patient). Injections were performed by a single experienced clinician under sterile conditions using a 30-gauge needle.

The Center of Force (CoF) represents the geometric center of the total occlusal force distribution, measured using the T-Scan Novus™ computerized occlusal analysis system (version 10.0.40; Tekscan, Inc., South Boston, MA, USA). CoF values closer to zero indicate greater bilateral occlusal balance. Within-group changes (T0 to T1) and between-group differences were assessed and compared between low-angle (GoGn/SN < 26°) and normal-angle (GoGn/SN 26-38°) subgroups.

Anterior force percentage is defined as the combined occlusal force distribution of the anterior teeth, and posterior force percentage as the combined force distribution of the posterior teeth. Both were measured using the T-Scan Novus™ system at baseline (T0) and day 15 post-injection (T1). Within-group changes and between-group differences in anterior-posterior force distribution were evaluated and compared between low-angle and normal-angle subgroups.